Thalidomide for Patients with Recurrent Lymphoma

Barbara Pro*, Anas Younes, Maher Albitar, Nam H. Dang, Felipe Samaniego, Jorge Romaguera, Peter McLaughlin, Fredrick B. Hagemeister, Maria A. Rodriguez, Marilyn Clemons, Fernando Cabanillas

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


BACKGROUND. Thalidomide has significant clinical activity in patients with multiple myeloma. However, its activity against other lymphoid tumors is unknown. The authors reported their experience with thalidomide in patients with recurrent/refractory non-Hodgkin lymphoma and in patients with Hodgkin disease. METHODS. Nineteen patients (median age, 62 years) who had undergone a median of 5 previous treatment regimens were treated with escalating doses of thalidomide (200-800 mg per day) until disease progression or prohibitive toxicity was observed. The authors measured serum levels of angiogenesis factors before and after treatment. RESULTS. One patient (5%) with evidence of recurrent gastric mucosa-associated lymphoid tissue lymphoma achieved a complete response, and 3 patients (16%) achieved stable disease. CONCLUSIONS. The current study suggests that thalidomide has limited single-agent activity in heavily pretreated patients with recurrent or refractory lymphoma.

Original languageEnglish (US)
Pages (from-to)1186-1189
Number of pages4
Issue number6
StatePublished - Mar 15 2004


  • Hodgkin disease
  • Multiple myeloma
  • Non-Hodgkin disease
  • Single-agent activity
  • Thalidomide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Thalidomide for Patients with Recurrent Lymphoma'. Together they form a unique fingerprint.

Cite this